Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Thorax|August 6, 2010
Cardiovascular events in patients with COPD: TORCH study resultsPeter M A Calverley, Julie A Anderson, Bartolome Celli, et al.
American Journal of Respiratory and Critical Care Medicine|April 1, 2022
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical TrialsPeter M A Calverley, Fernando J Martinez, Jørgen Vestbo, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 19, 2019
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPDCourtney Crim, Michael L Watkins, Eric D Bateman, et al.
Clinical Trials (London, England)|May 23, 2020
Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trialRobert A Wise, Julie A Anderson, Pierre Amarenco, et al.
ERJ Open Research|June 4, 2021
Safety data in randomised real-world evidence studies: Salford Lung Study learningsCatherine Harvey, Ashley Woodcock, Jørgen Vestbo, et al.
American Journal of Respiratory and Critical Care Medicine|September 23, 2020
Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic ReviewBartolome R Celli, Julie A Anderson, Nicholas J Cowans, et al.
European Heart Journal|August 14, 2018
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trialJames Brian Byrd, David E Newby, Julie A Anderson, et al.
Respiratory Medicine|September 27, 2017
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trialCourtney Crim, Peter M A Calverley, Julie A Anderson, et al.
ERJ Open Research|March 1, 2019
Impact of pre-enrolment medication use on clinical outcomes in SUMMITJørgen Vestbo, Mark Dransfield, Julie A Anderson, et al.
American Journal of Respiratory and Critical Care Medicine|July 25, 2017
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular RiskPeter M A Calverley, Julie A Anderson, Robert D Brook, et al.
Pageof 9